Mucosal damage: A major risk factor for severe complications after cytotoxic therapy

Seminars in Oncology

Volumn 31, Issue SUPPL. 8, 2004, Pages 35-44

  Peterson, Douglas E ^a   Cariello, Anna ^b  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; AMPHOTERICIN B; ANESTHETIC AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; BETA CAROTENE; BUSULFAN; CARBOPLATIN; CHLORHEXIDINE; CISPLATIN; COLISTIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 20; FLUOROURACIL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INDOMETACIN; INTERLEUKIN 11; KERATINOCYTE GROWTH FACTOR; MELPHALAN; PENTOXIFYLLINE; PROSTAGLANDIN E2; PROTEGRIN; SILVER NITRATE; SUCRALFATE; TOBRAMYCIN; TRANSFORMING GROWTH FACTOR BETA3; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CRYOTHERAPY; DIGESTIVE SYSTEM INJURY; DRUG DOSE REDUCTION; DRUG EFFECT; ESOPHAGITIS; GASTROINTESTINAL MUCOSA; HEAD AND NECK CANCER; HUMAN; LUNG NON SMALL CELL CANCER; MUCOSA INFLAMMATION; NEUTROPENIA; PARENTERAL NUTRITION; PRIORITY JOURNAL; TOPICAL ANESTHESIA; TREATMENT OUTCOME;

EID: 3042759701     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2004.04.006     Document Type: Conference Paper

References (56)

1. Squier C.A., Kremer M.J. Biology of oral mucosa and esophagus. J Natl Cancer Inst Monogr. 29:2001;7-15
2. Biron P., Sebban C., Gourmet R., et al. Research controversies in management of oral mucositis. Support Care Cancer. 8:2000;68-71
3. Knox J.J., Puodziunas A.L., Feld R. Chemotherapy-induced oral mucositis. Prevention and management. Drugs Aging. 17:2000;257-267
4. Epstein J.B., Tsang A.H., Warkentin D., et al. The role of salivary function in modulating chemotherapy-induced oropharyngeal mucositis A review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 94:2002;39-44
5. Sonis S.T. Mucositis as a biological process A new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol. 34:1998;39-43
6. Elting L.S., Cooksley C., Chambers M., et al. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer. 98:2003;1531-1539
7. Adelstein D.J., Saxton J.P., Lavertu P., et al. Maximizing local control and organ preservation in advanced squamous cell head and neck cancer (SCHNC) with hyperfractionated radiation (HRT) and concurrent chemotherapy. Proc Am Soc Clin Oncol. 20:2001;224a. (abstr 893)
8. Chougule P.B., Ready N., Akhtar M., et al. Concurrent chemoradiotherapy for advanced inoperable head and neck cancer A three year follow-up. Proc Am Soc Clin Oncol. 20:2001;232a. (abstr 927)
9. Ballivy O., Soulières D., Gauthier M.S., et al. Treatment related acute toxicities and observance for head and neck (H&N) cancer patients treated with two different concurrent chemo-radiotherapy regimen Retrospective analysis from CHUM-Hopital Notre-Dame. Proc Am Soc Clin Oncol. 21:2002;188b. (abstr 2572)
10. Picozzi V.J., Pohlman B.L., Morrison V.A., et al. Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma. Oncology (Huntingt). 15:2001;1296-1306. discussion 1310-1311, 1314
11. Wardley A.M., Jayson G.C., Swindell R., et al. Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue. Br J Haematol. 110:2000;292-299
12. Goldberg S.L., Pineiro L., Schuster M.W., et al. Identification of transplant conditioning regimens of high mucositis potential. Proc Am Soc Clin Oncol. 21:2002;368a. (abstr 1468)
13. Kalemkerian G.P., Belzer K., Wozniak A.J., et al. Phase I trial of concurrent thoracic radiation and continuous infusion cisplatin and etoposide in stage III non-small cell lung cancer. Lung Cancer. 25:1999;175-182
14. Nguyen N.P., Leonardo J.M., Karlsson U., et al. Efficacy of combined radiation, paclitaxel and carboplatin for locally advanced non-small cell lung carcinoma. Anticancer Res. 22:2002;3429-3436
15. Bellm L.A., Epstein J.B., Rose-Ped A., et al. Patient reports of complications of bone marrow transplantation. Support Care Cancer. 8:2000;33-39
16. Sonis S.T., Oster G., Fuchs H., et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol. 19:2001;2201-2205
17. Pettengell R., Gurney H., Radford J.A., et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma A randomized controlled trial. Blood. 80:1992;1430-1436
18. Brockstein B., Haraf D.J., Stenson K., et al. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck. J Clin Oncol. 16:1998;735-744
19. Herchenhorn D., Araujo C.M., Dias F.L., et al. Phase I study of gemcitabine (GEM) and cisplatin (CIS) combined with radiotherapy (RT) for stage IV squamous cell carcinoma of the head and neck (SCCHN). Proc Am Soc Clin Oncol. 21:2002;1916. (abstr 2581)
20. Symonds R.P., Pulliam J., Redman R., et al. Endpoint evaluation of trials to reduce the severity of treatment induced oral mucositis. Proc Am Soc Clin Oncol. 21:2002;236a. (abstr 942)
21. Kim E.S., Khuri F.R. Docetaxel and radiation as combined-modality therapy. Oncology (Huntingt). 16:(suppl 6):2002;97-105
22. Mudad R., Ramsey M., Kovitz K., et al. Concomitant weekly docetaxel, cisplatin and radiation therapy in locally advanced non-small cell lung cancer A dose finding study. Lung Cancer. 39:2003;173-177
23. Lee K.W., Kim D.Y., Yun T., et al. Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients comparison of treatment outcomes between young and elderly patients and the significance of doxorubicin dosage. Cancer. 98:2003;2651-2656
24. Budman D.R., Berry D.A., Cirrincione C.T., et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst. 90:1998;1205-1211
25. Rapoport A.P., Miller Watelet L.F., Linder T., et al. Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplants. J Clin Oncol. 17:1999;2446-2453
26. Sonis S.T., Eilers J.P., Epstein J.B., et al. Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Mucositis Study Group. Cancer. 85:1999;2103-2113
27. Trotti A., Byhardt R., Stetz J., et al. Common toxicity criteria: Version 2.0. An improved reference for grading the acute effects of cancer treatment: Impact on radiotherapy. Int J Radiat Oncol Biol Phys. 47:2000;13-47
28. McGuire D.B., Peterson D.E., Muller S., et al. The 20 item oral mucositis index Reliability and validity in bone marrow and stem cell transplant patients. Cancer Invest. 20:2002;893-903
29. Filicko J., Lazarus H.M., Flomenberg N. Mucosal injury in patients undergoing hematopoietic progenitor cell transplantation New approaches to prophylaxis and treatment. Bone Marrow Transplant. 31:2003;1-10
30. Clarkson J.E., Worthington H.V., Eden O.B. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev CD000978. 2003
31. Worthington H.V., Clarkson J.E., Eden O.B. Interventions for treating oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev CD001973. 2002
32. Dazzi C., Cariello A., Giovanis P., et al. Prophylaxis with GM-CSF mouthwashes does not reduce frequency and duration of severe oral mucositis in patients with solid tumors undergoing high-dose chemotherapy with autologous peripheral blood stem cell transplantation rescue A double blind, randomized, placebo-controlled study. Ann Oncol. 14:2003;559-563
33. Cascinu S., Fedeli A., Fedeli S.L., et al. Oral cooling (cryotherapy), an effective treatment for the prevention of 5-fluorouracil-induced stomatitis. Eur J Cancer B Oral Oncol. 30B:1994;234-236
34. Nottage M., McLachlan S.A., Brittain M.A., et al. Sucralfate mouthwash for prevention and treatment of 5-fluorouracil-induced mucositis A randomized, placebo-controlled trial. Support Care Cancer. 11:2003;41-47
35. Castagna L., Benhamou E., Pedraza E., et al. Prevention of mucositis in bone marrow transplantation A double blind randomised controlled trial of sucralfate. Ann Oncol. 12:2001;953-955
36. Pitten F.A., Kiefer T., Buth C., et al. Do cancer patients with chemotherapy-induced leukopenia benefit from an antiseptic chlorhexidine-based oral rinse? A double-blind, block-randomized, controlled study. J Hosp Infect. 53:2003;283-291
37. Okuno S.H., Foote R.L., Loprinzi C.L., et al. A randomized trial of a nonabsorbable antibiotic lozenge given to alleviate radiation-induced mucositis. Cancer Chemother Pharmacol. 79:1997;2193-2199
38. Barker G.J. Current practices in the oral management of the patient undergoing chemotherapy or bone marrow transplantation. Support Care Cancer. 7:1999;17-20
39. Mueller B.A., Millheim E.T., Farrington E.A., et al. Mucositis management practices for hospitalized patients national survey results. J Pain Symptom Manage. 10:1995;510-520
40. Farrell C.L., Bready J.V., Rex K.L., et al. Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res. 58:1998;933-939
41. Meropol N.J., Somer R.A., Gutheil J., et al. Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy potential role as mucosal protectant. J Clin Oncol. 21:2003;1452-1458
42. Clarke S.J., Abdi E., Davis I.D., et al. Recombinant human keratinocyte growth factor (rHuKGF) prevents chemotherapy-induced mucositis in patients with advanced colorectal cancer A randomized phase II trial. Proc Am Soc Clin Oncol. 20:2001;383a. (abstr 1529)
43. Durrant S., Pico J.L., Schmitz N.B., et al. A phase I study of recombinant keratinocyte growth factor (rHuKGF) in lymphoma patients receiving high-dose chemotherapy (HDC) with autologous peripheral blood progenitor cell transplantation (autoPBPCT). Blood. 94:(suppl 1):1999;708a. (abstr 3130)
44. Spielberger R., Stiff P., Emmanouilides C., et al. Efficacy of recombinant human keratinocyte growth factor (rHuKGf) in reducing mucositis in patients with hematologic malignancies undergoing autologous peripheral blood progenitor cell transplantation (auto-PBPCT) after radiation-based conditioning-Results of a phase 2 trial. Proc Am Soc Clin Oncol. 20:2001;7a. (abstr 25)
45. Stiff P., Bensinger W., Emmanouilides C., et al. Treatment of mucositis with palifermin improves patient function and results in clinically meaningful reduction in mouth and throat soreness (MTS) Phase III results. Blood. 102:2003;194a. (abstr 676)
46. Spielberger R., Emmanouilides C., Stiff P., et al. Use of recombinant human keratinocyte growth factor (rHuKGF) can reduce severe oral mucositis in patients (pts) with hematologic malignancies undergoing autologous peripheral blood progenitor cell transplantation (auto-PBPCT) after radiation-based conditioning. Proc Am Soc Clin Oncol. 2003;. (abstr 3642). Available at: www.asco.org (accessed April 26, 2004)
47. Emmanouilides C., Spielberger R., Stiff P., et al. Palifermin treatment of mucositis in transplant patients reduces health resource use phase 3 results. Blood. 102:2003;251a. (abstr 883)
48. Peterson D.E., Petit R.G. Phase III study AES-14 in chemotherapy patients at risk for mucositis. Proc Am Soc Clin Oncol. 22:2003;725. (abstr 2917)
49. Giles F.J., Miller C.B., Hurd D.D., et al. A phase III, randomized, double-blind, placebo-controlled, multinational trial of iseganan for the prevention of oral mucositis in patients receiving stomatotoxic chemotherapy (PROMPT-CT trial). Leuk Lymphoma. 44:2003;1165-1172
50. Sonis S.T., Lindquist L., Van Vugt A., et al. Prevention of chemotherapy-induced ulcerative mucositis by transforming growth factor beta 3. Cancer Res. 54:1994;1135-1138
51. Foncuberta M.C., Cagnoni P.J., Brandts C.H., et al. Topical transforming growth factor-beta3 in the prevention or alleviation of chemotherapy-induced oral mucositis in patients with lymphomas or solid tumors. J Immunother. 24:2001;384-388
52. Sonis S., Edwards L., Lucey C. The biological basis for the attenuation of mucositis The example of interleukin-11. Leukemia. 13:1999;831-834
53. Alvarez E., Fey E.G., Valax P., et al. Preclinical characterization of CG53135 (FGF-20) in radiation and concomitant chemotherapy/radiation-induced oral mucositis. Clin Cancer Res. 9:2003;3454-3461
54. World Health Organization. Handbook for Reporting Results of Cancer Treatment. 1979;15-22 World Health Organization, Geneva
55. Assessing stomatitis Refinement of the Western Consortium for Cancer Nursing Research (WCCNR) stomatitis staging system. Can Oncol Nurs J. 8:1998;160-165
56. Common Terminology Criteria for Adverse Events v3.0 (CTCAE) Cancer Therapy Evaluation Program. 2003;. Available at: http://ctep.cancer.gov. (published December 12, )